阿尔茨海默病患者治疗前后β-淀粉样蛋白和胰岛素含量变化

A comparision between β-AP and INS in the patient with Alzheimer disease by different treatment methods

目的测定阿尔茨海默病(AD)患者治疗前后β-淀粉样蛋白(β-AP)和胰岛素(INS)含量变化,进而比较不同药物治疗效果。方法用放免法测定60例患者和30例正常对照组的β-AP和INS含量,并按不同药物治疗前后分组。结果轻度痴呆认知功能、日常生活能力,躯体并发症发生率与中度、重度痴呆比较差异有显著意义(P<0．05);AD组血清β-AP含量均明显高于正常对照组(P<0．01),治疗后含量均低于治疗前(P<0．05～0．01);4-8个月脑活素组β-AP的含量明显高于脑复康组(P<0．05～0．01);老年性痴呆胰岛素含量明显低于血管性痴呆组和正常对照组(P<0．05);脑活素治疗AD病疗效高于脑复康。结论阿尔茨海默病患者治疗前后测定β-AP和INS含量变化,对病情的预测和疗效的评定有一定的帮助。

Objective To check the change of content of serum beta-apoliprotien（β-AP） and insulin（INS） in the patient with Alzheimer disease,and to reflect the effect of using different drug. Methods 60 cases of this disease and 30 cases of the control group were been derecrcd by radioimmunoassay（RIA）. Results The content of β-AP in Alzheimer disease（AD） was obviously higher than that in control groups（ P〈 0.01 ）,the comparison of content between β-AP and INS was positive relationship（ r = 0.59, r = 0.61, P 〈 0.05 ）. Comparing the β-AP, INS, we found their contents was obviously lower than those of pretreatment. It had effect on the patient when using cerebrolysin and paracetam,but the former was better than the later. Conclusion The theraputic of cerebrolysin can get the better treatment than the paracetam,for the patient with Alzheimer disease.